CryoPort/$CYRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CryoPort
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
- Ticker
- $CYRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 688
- Headquarters
- Brentwood, United States
- Website
- www.cryoportinc.com
CryoPort Metrics
BasicAdvanced
$1B
-
-$0.98
1.87
-
Price and volume
Market cap
$1B
Beta
1.87
52-week high
$21.78
52-week low
$7.61
Average daily volume
1.1M
Financial strength
Current ratio
2.037
Quick ratio
1.914
Long term debt to equity
0.084
Total debt to equity
0.479
Interest coverage (TTM)
-15.35%
Profitability
EBITDA (TTM)
-3.874
Gross margin (TTM)
46.91%
Net profit margin (TTM)
-21.46%
Operating margin (TTM)
-14.40%
Effective tax rate (TTM)
-5.50%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-2.27%
Return on equity (TTM)
-7.44%
Valuation
Price to revenue (TTM)
5.368
Price to book
2.39
Price to tangible book (TTM)
3.18
Price to free cash flow (TTM)
-51.972
Free cash flow yield (TTM)
-1.92%
Free cash flow per share (TTM)
-0.396
Growth
Revenue change (TTM)
11.77%
Earnings per share change (TTM)
-177.52%
3-year revenue growth (CAGR)
-6.62%
3-year earnings per share growth (CAGR)
-4.55%
What the Analysts think about CryoPort
Analyst ratings (Buy, Hold, Sell) for CryoPort stock.
Analyst projections of the future price of CryoPort stock.
Bulls say / Bears say
Third-quarter revenue rose 14% year on year, commercial cell and gene therapy revenue grew 20%, and Cryoport raised its 2026 revenue guidance to $197–199 million. The stronger results suggest demand is improving across its core business. (Cryoport)
Cryoport supports 23 commercial therapies and a record 788 clinical trials, including 99 in Phase 3. If more of these programmes reach approval and scale up, the company could gain recurring logistics and service revenue. (Cryoport)
Life Sciences Services revenue grew 18%, including 25% growth in BioStorage and BioServices, while adjusted EBITDA turned positive at $1.1 million. Higher service volumes could help improve margins as Cryoport uses its expanded network more fully. (Cryoport)
The underlying business remains loss-making: the third-quarter loss from continuing operations widened to $10.9 million from $6.7 million a year earlier. Positive adjusted EBITDA has not yet translated into GAAP profitability. (Cryoport)
Four customer regulatory filings that management had expected in 2026 have slipped into 2027. Delayed filings can push back approvals and the resulting commercial logistics revenue. (The Motley Fool)
Cryoport generated $10.1 million of operating cash in the first nine months of 2026 but spent $24.3 million on property and equipment. That investment outlay exceeded operating cash generation, leaving less room for error if growth or profitability improvements stall. (Cryoport)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
CryoPort Financial Performance
Revenues and expenses
CryoPort Earnings Performance
Company profitability
Upcoming events
No upcoming events
CryoPort News
AllArticlesVideos
Funds containing CryoPort
Fund name | Fund size | $CYRX weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | $9.1B | 0.19% |
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.